Allarity Therapeutics expands in-house lab to add proteomics, cell line research

PUBT · 22h ago
Allarity Therapeutics expands in-house lab to add proteomics, cell line research
  • Allarity Therapeutics expanded its in-house medical laboratory to add proteomics and cell line research capabilities.
  • Build-out targets deeper mechanism-of-action work on lead asset stenoparib, a dual PARP and WNT pathway inhibitor in Phase 2.
  • New services broaden the lab’s external offering, adding to existing transcriptomics research and CLIA clinical testing.
  • nCounter Pro platform now supports proteomics via the Human Tumor Signaling Protein Panel, measuring about 300 protein targets.
  • Expansion is not expected to change cash runway, with management pointing to cost efficiencies from bringing more research in-house.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280800PRIMZONEFULLFEED1001274922) on September 28, 2026, and is solely responsible for the information contained therein.